Alteration of Gut Microbiome and Correlated Amino Acid Metabolism Contribute to Hyperuricemia and Th17-Driven Inflammation in Uox-KO Mice

Siyue Song†, Yu Lou†, Yingying Mao², Xianghui Wen¹, Moqi Fan¹, Zhixing He¹, Yang Shen⁴, Chengping Wen* and Tiejuan Shao*¹

¹ College of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China, ² School of Public Health, Zhejiang Chinese Medical University, Hangzhou, China, ³ The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China

Although gut dysbiosis had been demonstrated to be an important factor affecting hyperuricemia (HUA) and gout, little is known for its potential mechanistic connections. In this study, Uox-KO mice model that with spontaneously developed pronounced HUA and urate nephropathy was used to explore the pathophysiologic mechanism of microbiota alterations in HUA and gout with integrated multi-omics analysis. 16S rRNA gene sequencing was performed to characterize the characteristic bacteria, and untargeted LC/MS analysis was applied to reveal the featured metabolites. Our results showed there was a significant shift in gut microbiota composition and function in Uox-KO mice compared to WT mice and apparent metabolomics differences between the two groups. Among them, amino acids metabolism appears to play a critical role. Correlation analysis further revealed that the characteristic metabolites were strongly influenced by the discrepant bacterial genera. Furthermore, impairment of intestinal integrity and profound alterations in the profile of solute carrier family resulted in dysregulation of amino acids transportation, which subsequently impacted serum uric acid level and CD4⁺ Th17 driven inflammation. Together, these data indicate that gut dysbiosis promotes purine metabolism disorder and inflammation in Uox-KO mice. Remodeling the gut microbiota is a promising strategy to combat HUA and gout.

Keywords: gut microbiota, hyperuricemia (HUA), Gout, amino acid metabolism, T cell immunity

INTRODUCTION

Hyperuricemia (HUA) is a metabolic disorder caused by abnormal uric acid (UA) metabolism, and it has become the second most common metabolic disease with changes in lifestyle and dietary patterns (1). Gout is the most common complaint associated with HUA (2). Uncontrolled HUA and gout can cause significant joint and organ damage (3). It also promotes diabetes, metabolic...
syndrome, atherosclerosis, chronic kidney disease, and cardiovascular disease, increasing the public health burden and can be life-threatening in severe cases (4).

Although HUA and associated gout have been mainly defined as the result of insufficient kidney UA excretion, emerging evidence highlights the importance of the intestinal tract and colonized gut microbiota in the development of HUA and gout (5). Several transporters promoting UA secretion have been identified in the intestine (6). Gut microbiota and its metabolites have been proven to directly or indirectly participate in the metabolism of purine and UA (7–9). The complex interactions between intestinal microbiota and the host provide crucial insight into the pathogenesis of many inflammatory diseases including gout (5, 10). The intestine and gut microbiota have become a new target for the prevention and treatment of HUA and gout (11, 12).

On the other side, even though macrophages and neutrophils were considered to be the principal immune cells and the NLRP3 inflammasome was the major pathway involved in gout inflammation, recent studies emphasized an emerging role of T cell subsets in the pathogenesis of gout (13). It was reported that abnormal functions of several T cell subsets like Th17 and aberrant expressions of their signature cytokines existed in gout (14). Targeting pro-inflammatory T cells and corresponding cytokines is a promising preventive and therapeutic strategy for gout. However, the molecular and cellular mechanisms underlying the role of those T cell subsets in gout are largely elusive.

This study aims to investigate the mechanistic linkage between gut microbiota and HUA and gout. To this end, we developed a urate oxidase (Uox)-knockout (Uox−/−) mouse model which has been reported as a suitable model of HUA and more closely mimic purine metabolism in humans (2). We investigated the association between alteration of gut microbiota and gout, and probed the possible mechanistic links between intestinal microbiota and HUA and joint inflammation in the aspects of metabolites. We revealed that gut microbiota composition and amino acid (AA) metabolism are critical important for the catabolism of purine nucleotides and infiltration of CD4+ Th17 cells, which plays important roles in HUA and gouty inflammation. The elucidation of the mechanisms underlying the immune regulation by microbiota may hold promise for developing potential intervention strategies for HUA and gout patients.

MATERIALS AND METHODS

Animals and Disease Assessment

Male mice aged 6 to 8 weeks were used. Uox gene-deficient (Uox−/−, Uox-KO) mice on the background of C57BL/6 were obtained from Shanghai Southern Model Biotechnology Co., Ltd. Homozygous Uox−/− and Uox+/+ (Wild Type, WT) mice were generated by intercrossing heterozygous mice and genotyped using a PCR-based method (Table S1). Under standard environmental conditions, the mice were housed in the Laboratory Animal Center of Zhejiang Chinese Medical Animal Care (AAALAC). Experimental procedures were approved by the Laboratory Animal Management and Welfare Ethical Review Committee of Zhejiang Chinese Medical University (Permission number: 201904000105).

The concentration of serum uric acid (SUA), urinary uric acid (UUA), serum creatinine (Scr), and urinary creatinine (UCr), urinary total protein (UTP) and urinary albumin (U-Alb) were detected by an automatic biochemical analyzer (Hitachi 3100, Tokyo, Japan). Footpad swelling was measured, and the mechanical pain threshold was quantified as reported previously (15). The claw region of mice was analyzed with HE staining for conventional morphological evaluation and with immunohistochemistry (IHC) assay for colon tight-junction protein expression (Table S2). Transmission electron microscopy was used for the investigation of the functional morphology of intestinal villi.

Co-Housing Experiment and Fecal Microbiota Transplantation

For co-housing experiment, the male offspring were separated once the gene type of the mice were determined. Separated WT and KO mice were fed adaptively for about 3 weeks until the gut bacteria of each group were settled down. The co-housed WT and KO mice were then bred in the same cage for 8 weeks, while the regular WT and Uox-KO mice were bred in separate cages to avoid microbiota cross transfer. For fecal microbiota transplantation (FMT), fresh feces were collected from Uox-KO mice, immediately placed into PBS (1×) and steeped for 1 min. Then, the dissolved feces were centrifuged at 1000 g (4°C) for 3 min. The suspension was collected and 100 μL of bacterial suspension was then delivered to each recipient mouse via oral gavage within 10 min for 4 weeks.

DNA Extraction, 16S rRNA Gene Sequencing and Data Analysis

The middle colonic feces were collected, and total DNA was extracted using the QIamp DNA microbiome kit (Qiagen). The 16S rRNA gene (V3–V4 region) was sequenced using the Illumina novaseq platform. The clean sequences were clustered into operational taxonomic units (OTUs) at 97% similarity. Raw sequences were deposited in the Sequence Read Archive database (http://www.ncbi.nlm.nih.gov/sra), with the accession numbers ranging from SAMN21847327 to SAMN21847340 and SAMN21848825 to SAMN21848852. Alpha and beta diversity were analyzed by R software (4.0.5, vegan package). The linear discriminant analysis (LDA) effect size (LEfSe) method was performed to discover taxa differentially abundant between different groups. Spearman’s correlation was used to determine the correlation between the correlation of microbiota with clinical indicators in R software (4.0.5, psych package). The co-occurrence network was visualized by Cytoscape software (3.7.0). PICRUSt2 was utilized to predict functional profiles basing on Kyoto Encyclopedia of Genes and Genomes (KEGG). Pathway and network enrichment analyses of the differentially expressed SLCs were performed on Metascape (http://metascape.org) and
visualized by Cytoscape software. Mental’s r was adopted to compute the relationships between the microflora, gout symptoms, CD4⁺ T and metabolite functional composition.

**Untargeted Fecal, Serum, and Kidney Metabolomics Analysis (LC-MS)**
Fecal, renal, and serum metabolites were extracted with 20% methanol solution with vortex and sonication (16). All extracted metabolites were analyzed using an ultra-high pressure liquid chromatography (UPLC) coupled with a triple quadrupole time-of-flight (TOF) system (ABSCIEX-Triple TOF 5600; AB SCIEX, Framingham, MA, USA). The LC-MS analysis procedure was described in the supplementary material. MS raw data were converted into the mzML format using ProteoWizard and then processed using R package XCMS. Differential metabolites among the two groups were summarized and mapped into their biochemical pathways through metabolic enrichment and pathway analysis based on database search (KEGG).

**Transcriptome Analysis of SLC Transporters**
High-quality colonic RNA was extracted and used to construct the sequencing library. The RNA-seq library was constructed and subsequent transcriptome sequencing was performed by MajorBio Biotech Co., Ltd. (Shanghai, China) on an Illumina Hiseq X-ten sequencer. RNA-Seq data was read as described in the supplementary material (17). The differential expression was visualized by heat map using R software.

**Analysis of mRNA and Protein Expression**
Total RNA was extracted from the colon with Trizol reagent (Invitrogen) and reversed transcribed into complementary DNA (cDNA) using the random hexamers primers with HiFiScript cDNA Synthesis Kit. Real-time quantitative PCR (qPCR) was performed using SYBR Green Premix Pro Taq HS qPCR Kit with Roche LightCycler® 96 SW1.1 instrument. The 2⁻ΔΔCt method was used to calculate the relative expression level of each sample referring to internal β-actin expression. The sequence of primers is shown in Table S3.

Total protein was extracted from the colon with cold RIPA lysis buffer with protease and phosphatase inhibitors. Whole protein concentrations were detected by BCA protein assay. The detailed western blotting procedure was described in the supplementary material, and the primary antibodies used were listed in Table S4. The protein bands were visualized using an Odyssey Infrared Imaging System (LI-COR Biosciences). Image J was used to quantify protein grey value as a ratio to β-actin.

**Measurement of Cytokines**
The colon tissues were homogenized in cold PBS, and the supernatant was collected to determine the concentration of IFN-γ, TNF-α, IL-1β, IL-6, and IL-17 by ELISA kits following the manufacturer’s instructions. Serum levels of cytokines were measured as well.

**Isolation of CD4⁺ T-Cells From the Gut**
The luminal content was removed, and the sectioned intestine was washed with ice-cold PBS. The tissue was then cutted into 1-2 mm pieces and digested with 2 mg/ml Collagenase D (Cat#: 11088858001, Roche) and 2 mg/ml DNase I (Cat#: 10104159001, Sigma-Aldrich) in RPMI-1640 medium (Gibco) at 37°C for 40 min under slow rotation. The supernatants were filtered by 70 µm mesh. The collected cells were resuspended in 30% Percoll (Sigma) and carefully overlaid onto 70% Percoll. After centrifugation, the cell layers located between the two Percoll layers were collected. CD4⁺ T-cells were isolated using EasySep™ Mouse CD4 Positive Selection Kit II (Cat#: 18952, STEMCELL Technologies, Canada).

**Flow Cytometry Analysis of CD4⁺ T Cells**
Single-cell suspension of the intestine was prepared as described above and was used for the subsequent Fluorescence-activated cell sorting (FACS) analysis. The spleen samples were ground, filtered, and then suspended in 1 mL pre-cooled PBS (1×). The erythrocytes were lysed with lysis buffer, and the remained cells were washed and resuspended in FACS buffer (Cat#: 420201, Biolegend). Detailed procedure for FACS analysis was described in the supplementary material. Fluorescent-dye-conjugated antibodies used in this study are listed in Table S5. Relevant negative control, Fluorescence Minus One (FMO) control and each fluorescence compensation sample were used to adjust fluorescence compensation and identify the populations of interest. Cells were sorted on a BECKMAN COULTER flow cytometer (CytoFLEX S), and data were analyzed using FlowJo software (10.4.0).

**Statistical Analysis**
SPSS 26.0 was used for statistical difference analysis of the experimental data and an unpaired two-tailed Student’s test was applied for two-group comparisons. All data with error bar was expressed as mean ± SEM. GraphPad Prism 9.0 software was used for plotting. Nominal p values of the results were corrected several times using the Benjamini-Hochberg method, and p values below 0.05 after correction were considered statistically significant.

**RESULTS**

**Intestinal Bacterial Perturbation Plays Critical Roles in HUA and Gout**
Uox-KO mouse model, which spontaneously developed pronounced HUA and urate nephropathy and has been widely used in HUA and associated disorders (2), was used to assess the role of gut microbiota alteration in the pathogenesis of HUA and gout. Consistent with previous reports, we observed lower body weight (Figure S1A, p<0.01) and significantly elevated levels of SUA and UUA (Figures S1B, C, p<0.001) in Uox-KO mice. Inflammatory cell infiltration was observed in the Uox-KO mice footpad (Figure S1D). Animals that received monosodium urate (MSU) crystals showed increased footpad swelling and reduced mechanical pain threshold (Figures S1E–G, p<0.001 and p<0.01). Furthermore, reduced renal tubules, glomerular atrophy and peripheral fibrosis were observed (Figure S1H).
Kidney index (Figure S1I, \(p<0.05\)), UCr, U-TP, and U-Alb (Figures S1J–L, \(p<0.001\)) were significantly reduced while Scr was markedly raised (Figure S1M, \(p<0.01\)). The Uox-KO mice have stable elevated SUA levels and mimicking the symptoms of gout patients. It is a suitable model to investigate the underlying mechanism of HUA and gout.

To investigate if the gut microbiota plays any role in HUA and gout, we then compared the gut microbiota structure of Uox-KO mice and WT mice using 16S rRNA gene amplicon sequencing. Although there were no apparent differences in richness indices (Ace and Chao) or diversity indices (Simpson and Shannon) between Uox-KO mice and WT mice (Figure 1A), PCoA analysis from the OTU level revealed an apparent shift in the gut microbiota composition in Uox-KO mice (Figure 1B, \(p=0.003\)). We noted an expansion of Firmicutes (phylum), as well as a reduction of Verrucomicrobiota (phylum) relative abundance in Uox-KO mice compared to that in WT mice (Figure 1C). LefSe analysis demonstrated the genera Akkermansia, Butyricicoccus_UCG-009, Ruminococcus, Helicobacter were overrepresented in WT mice. In contrast, the genera Anaerotruncus, Anaeroplasma, Lachnospiraceae_ASF356, Eubacterium_ventriosum, Ileibacterium, Lachnospiraceae_UCG-001, Mucispirillum, and Roseburia were enriched in Uox-KO mice, the majority of which belong to the Firmicutes phylum (Figure 1D). Spearman correlation analysis further demonstrated that the abundance of Akkermansia and Butyricicoccus_UCG-009, the strains overexpressed in WT mice, were positively correlated to body weight but negatively correlated to SUA (Figure 1E, \(p<0.05\), \(r>0.5\) or \(r<-0.5\)). In contrast, the bacteria enriched in Uox-KO mice, particularly those from Firmicutes, were positively correlated with SUA and Scr, but negatively correlated with UTP, U-Alb and weight, implying the contribution of these bacteria to the pathogenesis of HUA and gout (Figure 1E).

We further confirmed these findings by a co-housing experiment, in which WT mice were co-housed with Uox-KO mice for 8 weeks. The co-housed WT mice displayed an increased SUA compared to that of the control WT mice (Figure 1F, \(p<0.01\), \(p=0.001\)), while the co-housed Uox-KO mice still maintained the elevated level of SUA. 16S rRNA amplicon analysis further confirmed the transfer of the colonic microbiota from Uox-KO mice to the co-housed WT animals (Figure 1G, \(p=0.001\)). The abundance of the strains that positively correlated to SUA, such as Ileibacterium, Anaerotruncus and Roseburia was significantly increased in co-housed WT mice, but remained the similar abundance in co-housed KO mice (Figure S2A, \(p<0.01\), \(p<0.05\)). In addition, to fully verify the effect of intestinal bacterial perturbation on HUA, we transplanted fecal microbiota of Uox-KO mice into WT mice by gavage for 4 weeks. In keeping with the co-housing experiment, WT-FMT mice showed a significantly increased SUA compared to normal WT mice (Figure 1H, \(p<0.01\)). WT-FMT mice possessed similar biological characteristics with Uox-KO mice, showing significantly increased UUA (Figure S2B, \(p<0.01\)) and markedly raised Scr (Figure S2C, \(p<0.05\)). Although no significant differences were observed in kidney index, UCr, U-TP, and U-Alb between normal WT and WT-FMT mice (Figures S2D–G), a decreasing tendency was detected in WT-FMT mice. The lack of significance may be due to insufficient FMT duration to cause kidney damage. These results fully certified that gut microbiota play an important role in hyperuricemia and gout. The long-term exposure to the specific bacteria from Uox-KO mice will cause the elevation of SUA.

The Gut Microbiota Affects Host Amino Acid Metabolism in Uox-KO Mice

PICRUST2 software was utilized to predict the functional gene compositions of gut microbiota based on 16S rRNA sequencing data. The results showed that most functional predicted categories are related to metabolic and cellular processes, which mainly involved in membrane transport, carbohydrate metabolism, and AA metabolism (Figure 2A). To further unveil the linkage between gut bacterial changes and metabolism alterations, we compared the fecal metabolic profiles of the two groups by untargeted LC-MS. As shown in Figure 2B, we observed a clear overall separation between two groups in the OPLS-DA analysis, and 444 differential fecal metabolites were found with VIP>1 (variable important in projection, VIP) and \(p<0.05\) (Figure 2C). In line with the predicted results by PICRUST2, the top twenty enriched pathways obtained in KEGG pathway analysis were mainly involved in AA biosynthesis and metabolism (Figure 2D). Deeper analysis disclosed that the relative abundance of eight fecal AAs, including isoleucine (\(p<0.01\)), tryptophan (\(p<0.01\)), valine (\(p<0.01\)), arginine (\(p<0.05\)), glutamine (\(p<0.01\)), tyrosine (\(p<0.001\)), glutamate (\(p<0.05\)), and aspartic acid (\(p<0.001\)), were significantly accumulated in Uox-KO mice (Figure 2E). Among these eight differentially expressed AAs, five of them are essential- or conditional essential- AAs, which cannot be synthesized endogenously and depend largely on the fermentation of gut microbiota. It is worthy to note that the abundance of most AAs, which increased in feces, was statistically decreased in serum (Figure S3A). On the other hand, we also checked the metabolic profile in kidney. We found no statistically significant differences in these renal AAs between the two groups (Figure S3B), suggesting the changed AA serum concentration in Uox-KO mice was most likely caused by the intestinal disorders of AA metabolism rather than renal metabolism.

To better interpret the correlation between fecal metabolome and microbiome changes, we conducted the correlation analysis of the discrepant bacterial genera and fecal AAs. There was a strong positive correlation between those altered bacteria, such as Mucispirillum, Eubacterium_ventriosum, Lachnospiraceae_UCG-001, Anaeroplasma, and Ileibacterium, and the changed fecal AAs, but has no significant correlation with unchanged AAs (Figure 2F). In addition, we also observed a significant correlation between gut microbiota and serum levels of AA (Figure S3C), and therefore speculated that the perturbation of gut microbiota contributes to altered serum AA metabolome. No obvious relationship between gut microbiota and renal levels of AA was detected (Figure S3D).
Changes in the gut microbiota composition with HUA and gout. (A) Species richness indices (ACE & Chao) and species diversity indices (Shannon & Simpson) were used to evaluate alpha diversity. (B) Principal coordinate analysis plot of beta diversity as measured by Bray-Curtis distance ($p=0.003$). (C) Mean relative abundance of taxa at phylum level. Legend lists only the top taxa. (D) A histogram of the LDA scores was computed for features that showed differential abundance between WT and Uox-KO mice. Only taxons with LDA scores $>2$ and $p<0.05$ are represented. (E) The correlation networks among disease indices and differential microorganisms. The line colors indicate positive correlation (red implementation) or negative correlation (green dashed line) ($p<0.05$, $r>0.5$ or $r<-0.5$). (F) SUA concentration of co-housed mice. (G) PCoA analysis of co-housed mice ($p=0.001$). Co-housed WT had the similar composition of the gut microbiota with Uox-KO mice. (H) SUA concentration of WT-FMT mice. Values are expressed as mean ± SEM. "ns" represents not significant; **$p<0.01$; ***$p<0.001$.
Disordered Amino Acid Metabolism Correlated With Disease and Along With Impaired SLCs Expression

AAs involve in the various biochemical processes including the biosynthesis of UA, and previous studies have demonstrated the associations of plasma AAs and HUA and gout (18). However, the investigation is limited on the contributions of disordered fecal AA to HUA and gout. We performed a series of Spearman correlation studies to elucidate the relationship between fecal AAs and disease indices. As shown in Figure 3A, most of the
altered fecal AAs were positively correlated with SUA, UUA, SCr, and footpad swelling degree in Uox-KO mice, while inversely correlated with body weight, UCr, U-TP and U-Alb. These results suggested the importance of impaired fecal AA metabolism in the pathogenesis of HUA and gout. Although no correlation with mechanical pain threshold was found in our study, it can be explained by the short time for measuring mechanical pain threshold after MSU injection.

Since the integrity of the intestinal barrier is essential for the absorption of nutrients and its dysfunction has been implicated in numerous gastrointestinal and non-gastrointestinal diseases (19), we even checked the integrity and inflammatory status of the

---

**FIGURE 3** | Impaired intestinal mucosal barrier in Uox-KO mice. (A) Analysis of Spearman’s rank correlation between 13 feces amino acids and gout symptoms. Positive correlations are displayed in red and negative correlations in blue. The intensity of the color is proportional to the correlation coefficient. *p < 0.05; **p < 0.01; & on behalf of VIP>1. (B) H&E-stained of colonic sections (Scale bar: 250 µm). The boxed areas are shown enlarged. (C) Transmission electron micrograph of the intestinal villa in colon of WT and Uox-KO mice (Scale bar: 500 nm). (D) Expression of ZO-1 and Occludin in the colon was measured by immunohistochemistry (Scale bar: 250 µm). (E) Heatmap of 56 differentially expressed SLC genes in colon between WT and Uox-KO mice based on RNA transcriptome sequencing. (F) qRT-PCR validation of mRNA expression of randomly chosen SLC genes in mice intestinal tissues. (G) Network of enriched terms: colored by cluster ID, where nodes that share the same cluster ID are typically close to each other; colored by p-value, where terms containing more genes tend to have a more significant p-value. Values are expressed as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
intestine. In line with our expectation, massive infiltration of inflammatory cells (Figure 3B), severe atrophy of the intestinal villi (Figure 3C), and loss of the tight junction proteins ZO-1 and Occludin (Figure 3D) were observed in Uox-KO mice. We next compared the gene expression profiling in the intestine by RNA transcriptome sequencing. We mainly focused on the alteration of the SLCs (Solute carrier, the membrane transporters for AAs transportation) family expression. Whole transcriptional analysis revealed profound alteration in the SLC family profile. Fifty-six SLC transporters displayed different expression patterns. Most of them were downregulated in Uox-KO mice (Figure 3E). Changes were confirmed by qPCR in a randomly chosen subset of SLCs (Figure 3F, p<0.05, p<0.01, p<0.001). What’s more, the expression of SLC22A11 and SLC17A3, the confirmed renal urate transporter, were also checked by qPCR (Figure 3F, p<0.05, p<0.01, p<0.001). Further pathway and network enrichment analyses of the differentially expressed SLCs showed that these SLC transporters belong to 20 pathways. Amino acid transport and modified amino acid transport pathways were significantly enriched, which is consistent with the results of metabolomics. In addition, urate metabolic process was also activated, indicating some unspecified SLCs were involved in the uric acid metabolism as well (Figure 3G and Table S6).

Amino-Acid Metabolism Disorders Perturb Intestinal T-Cell Homeostasis

It is well known that AAs are vital nutrients for T cells, and efficient transportation of exogenous AAs is the prerequisite for T-cell activation, differentiation, and function (20). We, therefore, hypothesized that the observed AAs disorders might be associated with T cell dysfunction. To test this hypothesis, we evaluated the proliferation of CD4+ T cells in the intestine of Uox-KO mice by FACS. It was subsequently found that the intestinal CD4+ T cell counts were quantitatively reduced and the percentage and absolute number of pro-inflammatory CD4+ IL-17+ (Th17) cells were increased in Uox-KO mice (Figures 4A, B, p<0.05), along with a decrease in the percentage and absolute number of CD4+ CD25+ Foxp3+ (Treg) cells and a significant increase in Th17/Treg ratio (Figures 4C, D, p<0.05, p<0.01). Consistent with the results of flow cytometry, ELISA analysis revealed the heightened levels of IFN-γ (p<0.01), TNF-α (p<0.05), IL-1β (p<0.01), IL-6 (p<0.05), and IL-17 (p<0.01) in intestinal homogenates of Uox-KO mice (Figure 4E). Similar phenotypes were also observed in the spleen of Uox-KO mice (Figures 4F–J).

Besides, the mantel test results indicated that the count of CD4+ T cells was significantly correlated with featured bacteria, differential fecal AAs, and disease indices (Figure 5A). These results suggested that gut microbiome perturbation plays a vital role in AA metabolism, which may affect the activation and differentiation of CD4+ T cells, and ultimately influence the occurrence and development of HUA and gout.

Depletion of Amino Acids Blunts CD4+ T Cells via AKT-mTOR Pathway

Several studies have reported that the influence of AA metabolism on T-cell fate decisions may largely depend on the mechanistic of rapamycin complex 1 (mTORC1) signaling (21). To this end, we adopted western blotting analysis and found the phosphorylation levels of AKT (Ser473) and mTOR (Ser2448) were dramatically increased in the intestine of Uox-KO mice (Figures 5A, B, p<0.01, p<0.001). We further isolated CD4+ T cells from the gut and verified this mechanistic pathway at the cell level (Figures 5C, D, p<0.05, p<0.01). In addition, to further clarify the role of amino acid deprivation in AKT activation, we also quantified the expression of SLCs in the isolated T cells by qPCR and observed a reduction in SLCs expression as well (Figure 5E, p<0.05, p<0.01, p<0.001), which is consistent with the results of the whole intestine. Taken together, these results suggested that the unavailability of amino acids caused by SLC transporters dysfunction led to the disorder of T cell proliferation and differentiation via the AKT-mTOR pathway, and as a consequence, the aberrant Th17 result in the intestinal inflammation in Uox-KO mice.

DISCUSSION

Cumulative evidence has demonstrated a great role for the gut microbiota and their metabolites in the pathogenesis of HUA and gout (22). However, the pathophysiologic mechanism of microbiota alterations in HUA and gout is not fully understood. In the current study, we proposed a conceptual advancement in understanding the mechanism of HUA and gout pathogenesis and revealed that dysbiosis of the gut microbiota may affect to the dysfunction of AA transportation and metabolism, which further promoted purine nucleotide cycle and Th17 cell infiltration (Figure 6).

Previous studies have suggested the direct or indirect involvement of bacterial metabolites, particularly short-chain fatty acids (SCFAs) and bile acids (BAs), in inflammatory disease. In the present study, we detected many fecal metabolites significantly altered in Uox-KO mice compared to WT mice. Among them, the most significant change occurred in AAs, particularly those in branched-chain AAs (BCAAs, valine, and isoleucine), α-ketoglutarate family (glutamate, glutamine, and arginine), and aromatic AAs (AAAs, tryptophan and tyrosine). The mutual interplay between AAs and gut bacteria has been extensively discussed (16, 23–25). For example, as the most abundant essential AAs, the levels of BCAAs are tightly correlated with certain specific bacteria such as Akkermansia (26, 27), which significantly depleted in Uox-KO mice. A very recent study reported that HUA and gout patients have distinct serum metabolomics signatures, and arginine metabolism appears to play a critical role (28). In our study, we discovered a panel of AAs were strongly related to HUA and gout in addition to arginine. For instance, BCAAs deficiency leads to oxidative stress and major increases in the metabolites of the purine nucleotide cycle (PNC). The PNC acts as a temporary purine nucleotide reservoir and is activated during high ATP utilization or impaired oxidative phosphorylation. Catabolism of the purine nucleotides ultimately leads to the uric acid production, suggesting the lower plasma BCAAs arouse the...
higher serum uric acid (29, 30). Additionally, glutamine is a major metabolite of the TCA cycle in energy metabolism and a precursor of urate synthesis. A defect of glutamine metabolism maybe was caused by accelerated purine production (28). What’s more, the disorder of aromatic amino acids metabolism is one of the leading causes of gout (31). It has been reported that the administration of tryptophan suppressed the elevation in SUA levels and increased urinary UA excretion by regulating the
metabolism of glycine to creatinine. The low serum tryptophan level maybe is an indicator of elevated UA synthesis (32). And last, tyrosine catalyzes the formation of deoxyribose of pyrimidine and purine ribonucleotides (33, 34).

In addition to the effect on purine metabolism and UA generation, AA auxotrophy has evolved to become an immunoregulatory control point. The deficiency of AAs has long been to impair immune function. It is the signal that
initiates the complete signaling response, which increase the susceptibility to many major infectious and inflammatory diseases (35). The activation, differentiation and function of T cells heavily rely on environmental AAs (36, 37). Although it is widely accepted that gout is an inflammatory disease characterized by urate crystal-induced NLRP3 inflammasome activation with up-regulated caspase-1 protease and IL-1β in macrophages, recent evidence has highlighted that serum IL-17 levels are significantly elevated in gout patients (38). IL-17 is an essential pro-inflammatory cytokine and is mainly secreted by the CD4+ Th 17 cells and subsets of innate lymphoid cells (39–41). Many studies have shown that Th17/Treg balance in intestinal mucosa plays a fundamental role in stabilizing gut immunological homeostasis and a shift Th17/Treg equilibrium towards the pro-inflammatory Th17 side is involved in the occurrence and development of several autoimmune disorders (41–44). The same phenomenon was observed in our Uox-KO mice, suggesting a pathogenic role of this specific CD4+ T cell subset in gout occurrence and development (45). In fact, an aspect that should not be omitted is that the presence of IL-17. IL-17 has been proposed to be the main contributor to chronic inflammation at the later stages of an inflammatory response due to its ability to sustain the recruitment of neutrophils and inflammatory monocytes. It also can amplify the inflammation induced by other cytokines, including IL-1, IL-6, IL-8, and TNF-α (46, 47). Several studies have reported that serum or urinary levels of IL-17 are significantly elevated in patients with rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, and autoimmune hepatitis (48–51). In the current study, the increased intestinal and serum levels of IL-17 were observed, along with the increase of IL-6, and TNF-α. We therefore hypothesized imbalanced Th17, and IL-17 are involved in the pathogenesis of gouty inflammation (38).

It is well-established that the intestinal barrier is ingeniously modulated by gut microbiota and host immune cells (52). Microbiota-derived metabolites, including SCFAs, AAs and BAs, are key mucosal barrier modulators (53–57). Disturbance of intestinal mucosal barrier function has been implicated in the pathogenesis and development of several disease states, including food allergies, inflammatory bowel disease, celiac disease, irritable bowel syndrome, metabolic syndrome, diabetes, non-alcoholic fatty liver disease and septic shock (58). Lv et al. (59) have reported that the altered microbiota composition in Uox-KO mice result in gut immune disorders and intestinal barrier dysfunction by upregulating TLR2/4/5 and promoting the release of IL-1β and TNF-α, which eventually promote the inflow of
microorganisms in systemic circulation and lead to systemic inflammation. In our study, we observed the dysregulated intestinal immunity and compromised intestinal barrier as well, and demonstrated that damaged intestinal integrity contributes to the pathogenesis of HUA. However, we proposed a mechanistic understanding that perturbations in the gut microbiota is involved in the occurrence and progression of disease through dysfunction of AA transportation and metabolism, which further promoted purine nucleotide cycle and Th17 cell infiltration.

What’s more, mucosae are also responsible for AA transportation across the plasma membrane, which is mainly mediated by the SLC transporters. SLC transporters are an important class of membrane proteins and mediate many essential physiological functions including nutrient uptake, ion influx/eﬄux and waste disposal. Among them, SLC22A11, SLC17A3 and SLC2A9 have been identified as renal urate transporter that influences serum urate concentration and urate excretion (34, 60–62). Our results suggested that suppressing of these urate transporters in the intestine might impact extra-renal urate excretion and thereby influence SUA level. Other transporters, such as SLC16A9, SLC17A4, and SLC17A1, are also known to be involved in the UA regulation (62). Here, we revealed the profound alteration in the SLC family profile in Uox-KO mice intestine and intestinal T cells. Many of them have not been reported previously to be involved in HUA and gout. In line with these ﬁndings, a two-sample Mendelian randomization analysis based on the results from genome-wide association studies including >140,000 individuals of European ancestry revealed the contribution of abnormal AA and aberrant SLCs to gout (Table S57). These ﬁndings highlight the role of the abnormal AAs transportation and metabolism by gut microbiota in HUA and gout, and suggest that intestinal dysbiosis due to an impaired intestinal barrier may be the key cause of metabolic disorders in HUA mice.

Meanwhile, our study has several limitations. Though we have revealed the potential role of gut microbiota in the pathogenesis of HUA and gout, future studies to identify the key bacteria strains that may account for metabolites and inﬂammation will be critical. Beyond the AAs that have been studied in this study, further exploration will be required to understand other mechanistic links connecting gut microbiota and gout. Additional cell and faecal transplant studies are needed to conﬁrm this fully. Future research into these critical questions may contribute to a better understanding of the pathogenesis of this disease and its broader potential clinical treatment.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

ETHICS STATEMENT

The animal study was reviewed and approved by the Laboratory Animal Management and Welfare Ethical Review Committee of Zhejiang Chinese Medical University.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting or revising the manuscript. TS and SS conceived and designed this study. SS, YL, YM, XW, MF, ZH, and YS were responsible for the acquisition and analysis of data. TS and SS drafted the manuscript. CW and TS approved the final version to be published. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by grants from the National Natural Science Foundation of China (81873145 & 82074248), the Natural Science Foundation of Zhejiang province (LY21H290005), and Graduate Scientiﬁc Research Fund Project of Zhejiang Chinese Medical University (2020YJ09).

ACKNOWLEDGMENTS

We appreciate the technical support from the Public Platform of Medical Research Centre, Academy of Chinese Medical Science, Zhejiang Chinese Medical University.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.804306/full#supplementary-material

REFERENCES

1. Galozzi P, Bindoli S, Doria A, Oliviero F, Sfriso P. Autoinflammatory Features in Gouty Arthritis. J Clin Med (2021) 10(9):1880. doi: 10.3390/jcm10091880
2. Lu J, Hao X, Yuan X, Cui L, Liu Z, Li X, et al. Knockout of the Urate Oxidase Gene Provides a Stable Mouse Model of Hyperuricemia Associated With Metabolic Disorders. Kidney Int (2018) 93(1):69–80. doi: 10.1016/j.kint.2017.04.031
3. Jaffe DH, Klein AB, Benis A, Flores NM, Gabay H, Morlock R, et al. Incident Gout and Chronic Kidney Disease: Healthcare Utilization and Survival. BMC Rheumatol (2019) 3:11. doi: 10.1186/s41927-019-0060-0
4. Liu N, Xu H, Sun Q, Yu X, Chen W, Wei H, et al. The Role of Oxidative Stress in Hyperuricemia and Xanthine Oxidoreductase (XOR) Inhibitors. Oxid Med Cell Longev (2021) 2021:1470380. doi: 10.1155/2021/1470380
5. Wang LM, Wang P, Teka T, Zhang YC, Yang WZ, Zhang Y, et al. (1)H NMR and UHPLC/Q-Orbitrap-MS-Based Metabolomics Combined With 16S rRNA Gut Microbiota Analysis Revealed the Potential Regulation Mechanism of Nuciferine in Hyperuricemia Rats. J Agric Food Chem (2020) 68(47):14059–70. doi: 10.1021/acs.jafc.0c04985
6. Hoque KM, Dixon EE, Lewis RM, Allan J, Gamble GD, Phipps-Green AJ, et al. The ABCG2 Q141K Hyperuricemia and Gout Associated Variant
24. Jana UK, Kango N, Pletschke B. Hemicellulose-Derived Oligosaccharides: Bi T, Feng R, Zhan L, Ren W, Lu X. ZiBuPiYin Recipe Prevented and Treated
23. Heat Stress Alters the Intestinal Microbiota and Metabolic Profiles in Mice. Front Microbiol (2021) 12:706772. doi: 10.3389/fmicb.2021.706772

22. Wang J, Chen Y, Zhong H, Chen F, Regenstein J, Hu X, et al. The Gut Microbiota Guts-Brain Axis Dialogue. Front Immunol (2021) 13(1):1–19. doi: 10.3389/fimmu.2021.779994

21. Guo Z, Zhang J, Wang Z, Ang KY, Huang S, Hou Q, et al. Intestinal Microbiota Inflammation and Epigenetic Regulation of T Helper 17/Regulatory T Cells: In Search of a Balanced Immune System. Ital J Dermatol Venerol (2021) 156(5):545–57. doi: 10.23736/S2784-8671.20.06580-3

20. Pearson C, Silva A, Seddon B. Exogenous Amino Acids are Essential for Inflammation by Microbiota Interactions With the Host. Nat Immunol (2017) 18(8):851–60. doi: 10.1038/ni.3780

19. Peters K, Dahlgren D, Lennernäs H, Sjöblom M. Melatonin-Activated MAPK Signaling in Vascular Smooth Muscle Cells. J Biol Chem (2012) 287(6):3833–40. doi: 10.1016/j.jbc.2011.06.056

18. Mahbub MH, Yamaguchi N, Takahashi H, Hase R, Amano H, Kobayashi-Lochem E, et al. mTOR Inhibition by Metformin Impacts Monosodium Urate Crystal-Induced Gouty Inflammation to Inhibit Antigen Presentation. Sci Rep (2021) 11:112562. doi: 10.1038/srep112562

17. Peters K, Willart M, van Nimwegen M, Bergen I, Poulout P, Virchow JC, et al. An Unexpected Role for Uric Acid as an Inducer of T Helper 2 Cell Immunity to Inhaled Antigens and Inflammatory Mediator of Allergic Asthma. Immunology (2011) 34(4):527–40. doi: 10.1111/j.1365-2567.2011.03015.x

16. Blander JM, Longman RS, Iliev ID, Sonenberg GF, Artis D. Regulation of Inflammation by Microbiota Interactions With the Host. Nat Immunol (2017) 18(8):851–60. doi: 10.1038/ni.3780

15. Kirkwood JS, Lebold KM, Miranda CL, Wright CL, Miller GW, Tanguay RL, et al. Vitamin C Deficiency Activates the Purine Nucleotide Cycle in Zebrafish. J Biol Chem (2012) 287(36):30333–41. doi: 10.1016/j.jbc.2012.06.049

14. Raucci F, Iqbal AJ, Saviano A, Minosi P, Piccolo M, Iraze C, et al. IL-17A Neutralizing Antibody Regulates Monosodium Urate Crystal-Induced Gouty Inflammation. Pharm Res (2019) 147:104351. doi: 10.1007/s11095-019-04351-5

13. Wen C, Li S, Wang J, Zhu Y, Zong X, Wang Y, et al. Heat Stress Alters the Intestinal Microbiota and Metabolic Profiles in Mice. Front Microbiol (2021) 12:706772. doi: 10.3389/fmicb.2021.706772

12. Guo Z, Zhang J, Wang Z, Ang KY, Huang S, Hou Q, et al. Intestinal Microbiota Distinguishes Gout Patients From Healthy Humans. Sci Rep (2016) 6:20602. doi: 10.1038/srep20602

11. Duncan JW, Granger JP, Ryan MJ, Drummond HA. Interleukin-17 Reduces Urinary Uric Acid Excretion: A Randomized, Single-Blind, Placebo-Controlled, Crossover Study. Nutrients (2019) 11(11):2562. doi: 10.3390/nu11112562

10. Kirkwood JS, Lebold KM, Miranda CL, Wright CL, Miller GW, Tanguay RL, et al. Vitamin C Deficiency Activates the Purine Nucleotide Cycle in Zebrafish. J Biol Chem (2012) 287(36):30333–41. doi: 10.1016/j.jbc.2012.06.049

9. Ni C, Li X, Wang L, Li X, Zhao J, Zhang H, et al. Lactic Acid Bacteria Strains via Microbiota-Gut-Brain Axis Dialogue. Mechanisms and Therapeutic Strategies. Front Immunol (2021) 12:706772. doi: 10.3389/fmicb.2021.706772

8. Sheng S, Chen J, Zhang Y, Qin Q, Li W, Yan S, et al. Structural and Functional Alterations of Gut Microbiota in Males With Hyperuricemia and High Levels of Liver Enzymes. Front Med (Lausanne) (2021) 8:779994. doi: 10.3389/fmed.2021.779994

7. Wen C, Li S, Wang J, Zhu Y, Zong X, Wang Y, et al. Heat Stress Alters the Intestinal Microbiota and Metabolic Profiles in Mice. Front Microbiol (2021) 12:706772. doi: 10.3389/fmicb.2021.706772

6. Medina-Vera I, Sanchez-Tapia M, Noriega-Lopez L, Granados-Porillo O, Guevara-Cruz M, Flores-Lopez A, et al. A Dietary Intervention With Functional Foods Reduces Metabolic Endotoxaemia and Attenuates Biochemical Abnormalities by Modifying Faecal Microbiota in People With Type 2 Diabetes. Diabetes Metab (2019) 45(2):122–31. doi: 10.1016/j.diabet.2018.09.004

5. Song et al. Altered Microbiome in Uox-KO Mice. J Nutr Metab (2017) 10.3389/fnut.2017.00417

4. Shao Z, Zhao F, Liu H, Xie Y, Zhao D, Li C. Transcriptomics and Metabolomics Reveal the Adaptation of Akkermansia Muciniphila to High Mucin by Regulating Energy Homeostasis. Sci Rep (2021) 11(1):9073. doi: 10.1038/s41598-020-79282-2

3. Shao Z, Wang C, Liang N, Liu Z, Li X, Zhu ZJ, et al. Serum Metabolomics Identifies Dysregulated Pathways and Potential Metabolic Biomarkers for Hyperuricemia and Gout. Arthritis Rheumatol (2021) 73(9):1738–48. doi: 10.1002/art.41733

2. Liu Y, Zhao F, Liu H, Xie Y, Zhao D, Li C. Transcriptomics and Metabolomics Reveal the Adaptation of Akkermansia Muciniphila to High Mucin by Regulating Energy Homeostasis. Sci Rep (2021) 11(1):9073. doi: 10.1038/s41598-020-79282-2

1. Liu Y, Zhao F, Liu H, Xie Y, Zhao D, Li C. Transcriptomics and Metabolomics Reveal the Adaptation of Akkermansia Muciniphila to High Mucin by Regulating Energy Homeostasis. Sci Rep (2021) 11(1):9073. doi: 10.1038/s41598-020-79282-2
43. Wen S, He L, Zhong Z, Zhao R, Weng S, Mi H, et al. Stigmasterol Restores the Balance of Treg/Th17 Cells by Activating the Butyrate-Pparγ Axis in Colitis. *Front Immunol* (2021) 12:741934. doi: 10.3389/fimmu.2021.741934

44. Wang Y, Zhang J, Xu L, Ma J, Lu M, Ma J, et al. Modified Gegen Qianlian Decoction Regulates Treg/Th17 Balance to Ameliorate DSS-Induced Acute Experimental Colitis in Mice by Altering the Gut Microbiota. *Front Pharmacol* (2021) 12:756978. doi: 10.3389/fphar.2021.756978

45. Dai XJ, Tao JH, Fang X, Xia Y, Li XM, Wang YP, et al. Changes of Treg/Th17 Ratio in Spleen of Acute Gouty Arthritis Rat Induced by MSU Crystals. *Inflammation* (2018) 41(5):1955–64. doi: 10.1007/s10573-018-0839-y

46. Gaffen SL. An Overview of IL-17 Function and Signaling. *Cytokine* (2008) 43(3):402–7. doi: 10.1016/j.cytjo.2008.07.017

47. van den Berg WB, Miossec P. IL-17 as a Future Therapeutic Target for Rheumatoid Arthritis. *Nat Rev Rheumatol* (2009) 5(10):549–53. doi: 10.1038/nrrheum.2009.179

48. Gaffen SL. The Role of Interleukin-17 in the Pathogenesis of Rheumatoid Arthritis. *Curr Rheumatol Rep* (2009) 11(5):365–70. doi: 10.1007/s11926-009-0052-y

49. Kwan BC, Tam LS, Lai KB, Lai FM, Li EK, Wang G, et al. The Gene Expression of Type 17 T-Helper Cell-Related Cytokines in the Urinary Sediment of Patients With Systemic Lupus Erythematosus. *Rheumatol (Oxford)* (2009) 48(12):1491–7. doi: 10.1093/rheumatology/kep255

50. Schwab N, Zozulya AL, Kieseier BC, Toyka KV, Wiendl H. An Imbalance of Two Functionally and Phenotypically Different Subsets of Plasmaicytoid Dendritic Cells Characterizes the Dysfunctional Immune Response in Multiple Sclerosis. *J Immunol* (2010) 184(9):5368–74. doi: 10.4049/jimmunol.0903662

51. Yu H, Huang J, Liu Y, Ai G, Yan W, Wang X, et al. IL-17 Contributes to Autoimmune Hepatitis. *J Huazhong Univ Sci Technolog Med Sci* (2010) 30(4):443–6. doi: 10.1007/s11596-010-0446-0

52. Okumura R, Takeda K. Maintenance of Intestinal Homeostasis by Mucosal Barriers. *Inflamm Regener* (2018) 38:5. doi: 10.1186/s41232-018-0063-z

53. Yang W, Yu T, Huang X, Bilotta AJ, Xu L, Lu Y, et al. Intestinal Microbiota-Derived Short-Chain Fatty Acids Regulation of Immune Cell IL-22 Production and Gut Immunity. *Nat Commun* (2020) 11(1):4457. doi: 10.1038/s41467-020-18262-6

54. Scott NA, Andrusiak A, Andersen P, Lawson M, Alcon-Giner C, Leclaire C, et al. Antibiotics Induce Sustained Dysregulation of Intestinal T Cell Immunity by Perturbing Macrophage Homeostasis. *Sci Transl Med* (2018) 10(464):eaao4755. doi: 10.1126/scitranslmed.aao4755

55. Zeng H, Chi H. Metabolic Control of Regulatory T Cell Development and Function. *Trends Immunol* (2015) 36(1):3–12. doi: 10.1016/j.it.2014.08.003

56. An JH, Cho DH, Lee GY, Kang MS, Kim SJ, Han SN. Effects of Vitamin D Supplementation on CD4(+) T Cell Subsets and mTOR Signaling Pathway in High-Fat-Diet-Induced Obese Mice. *Nutrients* (2021) 13(3):796. doi: 10.3390/nu13030796

57. Song X, Sun X, Oh SF, Wu M, Zhang Y, Zheng W, et al. Microbial Bile Acid Metabolites Modulate Gut RORγ(+) Regulatory T Cell Homeostasis. *Nature* (2020) 577(7790):410–5. doi: 10.1038/s41586-019-1865-0

58. Sharkey KA, Beck PL, McKay DM. Neuroimmunophysiology of the Gut: Advances and Emerging Concepts Focusing on the Epithelium. *Nat Rev Gastroenterol Hepatol* (2018) 15(12):765–84. doi: 10.1038/s41575-018-0051-4

59. Lv Q, Xu D, Zhang X, Yang X, Zhao P, Cui X, et al. Association of Hyperuricemia With Immune Disorders and Intestinal Barrier Dysfunction. *Front Physiol* (2021) 11:524236. doi: 10.3389/fphys.2020.524236

60. Stiburkova B, Ichida K, Sebesta I. Novel Homozygous Insertion in SLC2A9 Gene Caused Renal Hypouricemia. *Mol Genet Metab* (2011) 102(4):430–5. doi: 10.1016/j.ymgen.2010.12.016

61. Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, et al. SLC2A9 is a Newly Identified Urate Transporter Influencing Serum Urate Concentration, Urate Excretion and Gout. *Nat Genet* (2008) 40(4):437–42. doi: 10.1038/ng.106

62. Vadaketh S, Kandi V. Probable Potential Role of Urate Transporter Genes in the Development of Metabolic Disorders. *Careus* (2018) 10(3):e2382. doi: 10.7759/careus.2382

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Copyright © 2022 Song, Lou, Mao, Wen, Fan, He, Shen, Wen and Shao.** This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.